ProCE Banner Activity

Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations

Conference Coverage
Slideset

Released: January 30, 2023

Expiration: January 29, 2024

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Seagen Inc.